What You'll Learn
Table of Contents
Four Names, Two Drugs
Start here, because everything else follows from it.
| Molecule | For type 2 diabetes | For weight management |
|---|---|---|
| Semaglutide | Ozempic | Wegovy |
| Tirzepatide | Mounjaro | Zepbound |
Ozempic and Wegovy are the same molecule. Mounjaro and Zepbound are the same molecule. There are two drugs on this page, not four.
Once you know that, a lot of what you have read stops being confusing. “Ozempic for weight loss” is semaglutide being used for something its weight-management sibling is licensed for. The shortages that hit one name and not the other were supply of the same compound being allocated between two labels.
Bottom line: If someone tells you they switched from Ozempic to Wegovy, they did not change medication. They changed which approval they are being prescribed under, and usually the dose.
Why Two Names For The Same Molecule
Regulators approve a drug for a specific use, and the manufacturer brands each approval separately. Same compound, different licence, different name, usually a different dose range.
That has three practical consequences.
Insurance treats them differently. A plan that covers a diabetes drug may not cover the identical molecule under its obesity label. This is the single most common reason people end up on one rather than the other.
The licensed doses differ. The weight-management versions generally go to higher doses than the diabetes versions, which is part of why the trial results are not interchangeable between labels.
Availability differs. Supply problems have repeatedly hit one label while the other stayed available, because allocation is decided per product.
The Head-To-Head Trial
Until recently these were compared by lining up separate trials, which is unreliable — different participants, different durations, different protocols. A trial has since compared them directly.
An open-label phase 3b trial in adults with obesity and without type 2 diabetes, comparing tirzepatide against semaglutide over 72 weeks. Mean reduction in body weight was −21.5% with tirzepatide versus −14.5% with semaglutide (p < 0.001). Tirzepatide also produced a higher proportion of participants reaching the 10%, 15%, 20% and 25% loss thresholds.
Read the trial on PubMed ↗Bottom line: One caveat worth stating: the trial was open-label, so participants and investigators knew which drug was being given. That is common in trials of injectables with different devices and schedules, and it is a real limitation rather than a fatal one — the size of the gap makes it unlikely that expectation alone explains it.
HealthRX — physician-supervised GLP-1 care
Four names, two drugs — and without insurance the branded versions run into four figures a year. Compounded semaglutide and tirzepatide are the cheaper route, and they go through the same prescriber review. They are not the branded products and are not FDA-approved as finished drugs.
See what the intake involves →Disclosure: we earn a commission if you start a plan through this link, at no extra cost to you. It does not change what this page says. HealthRX dispenses compounded semaglutide and tirzepatide, which are pharmacy-prepared formulations, not the FDA-approved branded products. Nothing on this page is medical advice — that is what the provider review is for.
What Seven Percentage Points Actually Mean
A gap of roughly seven points sounds abstract. Put weight against it.
For someone starting at 100 kg, the difference between losing 21.5% and 14.5% is 21.5 kg against 14.5 kg — seven kilograms, over roughly seventeen months.
That is a genuine difference and it is fair to want the more effective drug. Two things temper it.
These are averages, and the spread around them is wide. Trial averages describe a group, not you. Plenty of people on semaglutide lose more than the tirzepatide average, and plenty on tirzepatide lose less than the semaglutide one.
Tolerability decides more than potency does. The most effective drug is the one a person can actually keep taking. Someone who stops the stronger option at month four because of side effects finishes behind someone who stayed on the other for seventy-two weeks.
Bottom line: The comparison that matters is not which drug wins a trial average. It is which one you can stay on, at a dose you tolerate, for long enough for the curve to flatten.
Which One You Actually Get
For most people this is not a choice made on efficacy data.
It is decided by what your prescriber judges appropriate, what your insurer covers, what is in stock, and whether you have type 2 diabetes — which changes which label applies to you.
Reading a comparison and asking for the winner by name is usually the wrong conversation to have at an appointment. The useful version is asking what you are eligible for, what is available, and what the plan is if the first option is not tolerated.
Important: This page describes what published trials found. It does not recommend a medication, a dose, or a supplier, and it is not a substitute for your prescriber. Any decision to start, stop, switch or change dose is a clinical one.
The Number None Of These Trials Reports
Every figure on this page is total body weight. That is what the trials measured and what the headlines repeat.
None of it tells you what the lost weight was made of.
Body-composition work on these medications consistently finds that a meaningful share of the loss is lean tissue rather than fat. A larger total loss is not automatically a better outcome if a larger share of it came from muscle — and the trials that produced the numbers above did not set out to answer that. Our muscle loss guide covers what the composition data shows.
This is the part of the comparison nobody runs, and it is the part you have some control over. Which drug you are prescribed is largely decided for you. How much of the loss is lean tissue is influenced by protein intake and resistance training, and those are yours.
Two more molecules come up constantly in this comparison and are not in it, because neither is approved. Retatrutide adds a third receptor and produced the largest weight loss yet trialled; cagrilintide works on amylin instead, and its head-to-head against semaglutide came in at 0.16 percentage points. Both are covered in the peptide research section.
